// App-Quantinova.ai

: COMBINATION OF FLOTETUZUMAB, A CD123 X CD3 BISPECIFIC DART® MOLECULE, AND BLINATUMOMAB, A CD19 X CD3 BITE MOLECULE, TO PREVENT ANTIGEN ESCAPE IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Researchers

Presenter

  • Dragana Slavkovic Lukic

Principal Investigators

  • Johannes Duell

  • Jan Davidson-Moncada

  • Andreas Schlagowsky

  • Hermann Einsele

  • Monika Szczepanowski

  • Denis M. Schewe

  • Monika Brggemann

  • Max S. Topp

Medical Centers

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Macrogenics, INC., Rockville, United States

  • Klinik fur Innere Medizin I, Universitatsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany

  • Klinik fur Innere Medizin I, Universitatsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany

Locations

  • Germany

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Cluster of Differentiation 19

  • Cluster of Differentiation 2AP

Drug/Treatment

  • Blinatumomab

  • Flotetuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved